. 2015 Jan 13;4(1):9. doi: 10.1186/2193-1801-4-9

Table 4.

Grade 3 and 4 toxicities [n (%)] associated with NAC, evaluated at cycle 8 ^a

GROUPS (n = 92)	TOXICITY
GROUPS (n = 92)	NAILS*	HAND-FOOT*	PARESTHESIA	MYALGIA*	FATIGUE
A	6(20.0%)	1 (3.3%)	2 (6.6%)	7 (23.3%)	16 (53.3%)
(n = 30)	6(20.0%)	1 (3.3%)	2 (6.6%)	7 (23.3%)	16 (53.3%)
B	16 (47.1%)	7 (23.3%)	1 (2.9%)	1 (2.9%)	21 (61.7%)
(n = 34)	16 (47.1%)	7 (23.3%)	1 (2.9%)	1 (2.9%)	21 (61.7%)
C	1 (6.3%)	0 (0%)	2 (12.5%)	1 (6.3%)	9 (56.3%)
(n = 16)	1 (6.3%)	0 (0%)	2 (12.5%)	1 (6.3%)	9 (56.3%)
D	8 (66.7%)	1 (8.3%)	2 (16.6%)	0 (0%)	9 (75.0%)
(n = 12)	8 (66.7%)	1 (8.3%)	2 (16.6%)	0 (0%)	9 (75.0%)
(A + C)	7 (15.2%)	1 (2.2%)	4 (8.7%)	8 (17.4%)	25 (54.3%)
(n = 46)	7 (15.2%)	1 (2.2%)	4 (8.7%)	8 (17.4%)	25 (54.3%)
(B + D)	24 (52.2%)	8 (17.4%)	3 (6.5%)	1 (2.2%)	30 (65.2%)
(n = 46)	24 (52.2%)	8 (17.4%)	3 (6.5%)	1 (2.2%)	30 (65.2%)

^aSerious Adverse Events (SAEs) : n = 13; Suspected Unexpected Serious Adverse Reactions (SUSARs) : n = 1; Deaths : n = 0. NS : Not Significant.

*Statistically significant (Pearson Chi-Square Test). *Nail changes : A v B (χ ² = 5.173, p = 0.023); C v D (χ ² = 11.476, p = 0.007); A + C v B + D (χ ² = 14.060, p = 0.0002). *Hand-foot syndrome : A v B (χ ² = 4.338, p = 0.037); C v D (NS); A + C v B + D (χ ² = 6.035, p = 0.014). Paresthesia : A v B (NS); C v D(NS); A + C v C + D (NS). *Myalgia : A v B (χ ² = 9.572, p = 0.023); A + C v B + D (χ ² = 6.035, p = 0.014). Fatigue : A v B (NS); C v D (NS); A + C v B + D (NS).